Eosinophilic Asthma Treatment Market Size, Share & Trends Analysis Report By Product (Intravenous Infusion, Subcutaneous Injection), By Applications (Children, Adults, Teenagers), By End Use, By Region, and Segment Forecasts - 2035

Eosinophilic Asthma Treatment Market Overview

eosinophilic asthma treatment market size was valued at USD 26278.06 million in 2025 and is poised to grow from USD 36473.95 million in 2026 to USD 97532.91 million by 2035, growing at a CAGR of 38.8% during the forecast period (2026-2035).

The Eosinophilic Asthma Treatment Market is undergoing a major transition from broad anti-inflammatory management toward phenotype-directed biologic therapy. Severe eosinophilic asthma is increasingly identified through blood eosinophil measurements, exacerbation history and other type 2 inflammatory indicators, enabling clinicians to match eligible patients with targeted therapies. Current biologic approaches include IL-5, IL-5 receptor, IL-4/IL-13 and upstream inflammatory-pathway targeting, with several therapies available for patients aged 6 years and above and others beginning at 12 or 18 years. Subcutaneous Injection is estimated to represent approximately 89% of treatment-format demand in 2026 because most leading biologics can be delivered subcutaneously, while Intravenous Infusion accounts for approximately 11%. Adults represent an estimated 72% of application demand, reflecting the larger diagnosed severe-asthma population, broader treatment eligibility and accumulated disease burden. Longer dosing intervals are also becoming a major competitive factor, with available regimens ranging from every 2 weeks to once every 26 weeks.

The United States remains one of the most important national markets because of its established severe-asthma specialist network, biologic availability and comparatively rapid adoption of precision respiratory medicine. North America is estimated to account for approximately 41% of global treatment activity in 2026, with the U.S. contributing the majority. Treatment eligibility has expanded substantially in younger populations: selected biologic therapies for severe eosinophilic asthma are now indicated from 6 years of age, while newer long-acting treatment options are available from 12 years. The competitive environment includes AstraZeneca, GSK, Genentech (Roche Group) & Novartis, Regeneron Pharmaceuticals & Sanofi, and Teva Pharmaceuticals. A particularly important development occurred in December 2025, when a new severe eosinophilic asthma biologic with twice-yearly subcutaneous administration was approved in the U.S., reducing scheduled annual maintenance injections to only 2 after treatment initiation.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Subcutaneous Injection is expected to lead with approximately 89% share, supported by multiple biologic options offering administration intervals ranging from every 2 weeks to approximately every 26 weeks.
• Leading Application: Adults account for an estimated 72% of treatment demand because severe eosinophilic asthma is more extensively diagnosed and biologic eligibility is broader across the adult population.
• Leading Region: North America is estimated to hold approximately 41% share, supported by extensive biologic availability, specialist respiratory care infrastructure and established biomarker-based severe-asthma treatment pathways.
• Fastest Growing Region: Asia Pacific is projected to record the strongest expansion, with an estimated growth rate above 15% as biologic access and eosinophil testing increase across major healthcare systems.
• Technology Trend: Ultra-long-acting biologic treatment is reshaping administration schedules, with the newest extended-duration approach requiring only 2 maintenance injections annually compared with 12 or more for monthly therapies.
• Market Driver: Precision treatment is strengthening adoption as blood eosinophil thresholds such as 150 cells per microliter help identify patients most likely to benefit from selected targeted biologics.
• Competitive Landscape: The supplied competitive landscape includes 5 major company groups, with product differentiation increasingly centered on dosing frequency, pediatric eligibility, administration convenience and inflammatory-pathway targeting.
• Future Outlook: The stated 38.8% CAGR indicates substantial long-term potential through 2035 as biologic penetration expands and treatment intervals extend from approximately 2 weeks to as long as 26 weeks.

Latest Trends

Longer-duration biologic therapy is one of the most significant trends reshaping eosinophilic asthma management. Historically, biologic treatments required administration every 2 weeks, every 4 weeks or every 8 weeks depending on the therapeutic mechanism and patient characteristics. The introduction of a subcutaneous biologic administered once every 6 months represents a major change in treatment convenience. Its pivotal development program included 762 adult and adolescent patients across 331 clinical sites in 23 countries, demonstrating the increasingly global nature of severe-asthma biologic research. Reducing administration frequency from monthly treatment to twice-yearly maintenance can lower the number of scheduled treatment events from 12 to 2 annually. This 83% reduction in administration frequency has the potential to improve persistence while reducing logistical demands on patients and healthcare facilities. Subcutaneous Injection consequently represents approximately 89% of estimated treatment-format demand and is expected to strengthen its position as self-administration and extended-duration formulations advance.

Another important trend is the broader use of biomarker-guided treatment selection. Blood eosinophil counts of 150 cells per microliter or 300 cells per microliter are commonly used within clinical assessment and research to characterize eosinophilic inflammation and predict therapeutic response. The market is simultaneously shifting beyond a single inflammatory target. Anti-IL-5 and IL-5 receptor therapies directly address eosinophilic pathways, while IL-4/IL-13 and TSLP-directed approaches influence broader type 2 inflammatory processes. Pediatric treatment is also expanding: selected biologics are available for severe eosinophilic asthma from 6 years of age, while several advanced therapies cover patients aged 12 years and older. These changes are creating more individualized treatment pathways across Children, Teenagers and Adults rather than applying identical therapeutic strategies to all severe-asthma patients.

Market Dynamics

Driver

""Precision biologics are transforming severe eosinophilic asthma management.""

The strongest market driver is the increasing clinical use of biologic therapies specifically designed for inflammatory pathways associated with severe eosinophilic asthma. Conventional inhaled therapies remain fundamental to asthma management, but patients with persistent severe disease can experience recurrent exacerbations despite high-intensity background treatment. Biologics provide an additional mechanism for patients with measurable type 2 inflammation. Clinical selection increasingly considers eosinophil counts, exacerbation frequency and corticosteroid dependence. Thresholds such as 150 eosinophils per microliter at treatment initiation are incorporated into eligibility frameworks for selected therapies, while levels around 300 eosinophils per microliter are frequently used to characterize populations with stronger eosinophilic activity. This measurable biomarker framework gives physicians a practical method for identifying patients who may benefit from targeted treatment.

Broader age eligibility is also increasing the addressable population. Several subcutaneous biologics can now be used from 6 years of age, extending precision treatment beyond adults and teenagers. Adults still account for approximately 72% of estimated application demand, while Teenagers represent approximately 17% and Children approximately 11%. The expansion into younger populations creates longer treatment pathways and encourages earlier specialist intervention. Meanwhile, the stated market growth rate of 38.8% through 2035 reflects expectations that biologic penetration will increase significantly from current levels as diagnosis, specialist referral and payer acceptance improve.

Restraint

""Restricted biologic eligibility continues to limit broader patient access.""

A major restraint is that targeted biologic therapy is generally reserved for patients with severe or inadequately controlled asthma rather than the overall asthma population. Clinical pathways typically require evidence that conventional controller therapy has not achieved sufficient disease control before biologics are considered. Severe-asthma biologics are generally positioned around the highest treatment steps, meaning a patient may undergo multiple assessments before receiving targeted therapy. Blood eosinophil measurements, previous exacerbations, oral corticosteroid dependence and other clinical characteristics can influence eligibility. Even among people with severe asthma, industry estimates indicate biologic treatment penetration remains below 25%, demonstrating the substantial gap between potential eligibility and actual utilization.

Administration requirements and safety monitoring can also restrict adoption. Intravenous Infusion, representing an estimated 11% of format demand, requires greater healthcare infrastructure than a self-administered injection and may involve scheduled visits every 4 weeks. Subcutaneous products simplify administration, but dosing intervals still vary considerably from every 2 weeks to every 26 weeks. Hypersensitivity reactions, eosinophilic complications and other product-specific warnings require appropriate medical oversight. These considerations can be particularly important in Children and Teenagers, which collectively represent approximately 28% of estimated application demand.

Opportunity

""Long-acting therapies can significantly improve treatment convenience and persistence.""

The largest opportunity lies in reducing treatment burden through longer biologic dosing intervals. A therapy administered every 2 weeks can require approximately 26 scheduled doses annually, while a monthly regimen requires approximately 13 and an 8-week maintenance schedule approximately 6 to 7. A 26-week schedule reduces planned maintenance administration to approximately 2 injections per year. This difference creates substantial opportunities for manufacturers developing antibodies with longer half-lives or formulations capable of maintaining therapeutic activity for extended periods. It also benefits healthcare systems because fewer treatment encounters can reduce administrative workload and improve capacity for other respiratory services.

Geographic expansion offers another major opportunity. North America currently represents approximately 41% of estimated demand and Europe approximately 29%, meaning around 70% is concentrated in 2 developed regions. Asia Pacific accounts for approximately 22%, while Latin America and Middle East & Africa together contribute approximately 8%. Improved specialist access, eosinophil testing and biologic reimbursement in emerging healthcare systems could gradually reduce this concentration. Asia Pacific is particularly attractive because large populations in China, Japan, South Korea and other markets provide a substantial potential patient base. Multicountry clinical programs involving more than 20 countries also demonstrate that severe-asthma biologic development is already becoming geographically diversified.

Challenge

""Selecting the optimal biologic for each patient remains clinically complex.""

The growing number of targeted treatment pathways creates an important clinical challenge: identifying which mechanism is most appropriate for an individual patient. Severe asthma is heterogeneous, and elevated eosinophils can overlap with allergic inflammation, corticosteroid dependence and other type 2 characteristics. Available biologic mechanisms target IgE, IL-5, IL-5 receptor alpha, IL-4/IL-13 signaling and TSLP. Comparative research has evaluated outcomes among multiple mechanisms, but differences in trial populations and eligibility criteria can make direct comparisons difficult. Eosinophil levels above 300 cells per microliter may indicate a highly eosinophilic phenotype, yet additional biomarkers and comorbidities can influence treatment choice.

Maintaining adherence over multiple years is another challenge even when administration is infrequent. A treatment given every 4 weeks requires approximately 13 annual administration events, while an 8-week maintenance regimen requires around 6. Ultra-long-acting treatment reduces this frequency considerably, but healthcare providers must still track response, exacerbations and safety. Adults account for approximately 72% of demand and may have multiple comorbidities that complicate therapy selection. Children and Teenagers create additional challenges involving weight-based dosing, caregiver involvement and long-term treatment monitoring.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Intravenous Infusion: Intravenous Infusion accounts for an estimated 11% of the Eosinophilic Asthma Treatment Market. This format is associated with therapies that require administration in a controlled healthcare setting, providing direct professional oversight during treatment. A representative intravenous biologic regimen for severe eosinophilic asthma is administered approximately once every 4 weeks, translating into about 13 infusion visits during a full year of continuous treatment. The approach can be appropriate for patients who benefit from clinic-based administration and structured monitoring. However, intravenous delivery generally requires more infrastructure and patient time than subcutaneous treatment, contributing to its smaller market share. Adults account for most intravenous utilization because some infusion-based treatment pathways are limited to patients aged 18 years and older. As self-injectable and extended-duration biologics expand, the estimated 11% share of Intravenous Infusion may gradually decline despite continued clinical relevance for selected patients.

Subcutaneous Injection: Subcutaneous Injection dominates with an estimated 89% share because the majority of modern biologic options for eosinophilic asthma use this administration route. Dosing frequency ranges considerably, including every 2 weeks, every 4 weeks, every 8 weeks after loading and, most recently, approximately every 26 weeks for an ultra-long-acting therapy. The convenience difference is substantial: a biweekly schedule may involve approximately 26 annual injections compared with only 2 maintenance injections under a twice-yearly approach. Subcutaneous formulations can also enable home administration for eligible patients after appropriate training, reducing dependence on infusion centers. The format serves Adults, Teenagers and Children depending on individual product eligibility, with several treatments approved from 6 years of age. These advantages support the estimated 89% share and make subcutaneous delivery the principal platform for future biologic innovation.

By Applications

Children: Children represent an estimated 11% of market demand. Pediatric eosinophilic asthma treatment has expanded as selected biologics have received indications extending to patients aged 6 years and older. Pediatric management requires careful assessment because disease severity, body weight and dosing requirements can differ from adult treatment. For selected therapies, children between 6 and 11 years may receive different doses according to weight thresholds such as 35 kilograms. The expansion of biologic eligibility below 12 years provides an important treatment pathway for children with severe disease that remains inadequately controlled despite conventional therapy. Subcutaneous Injection dominates this segment because currently relevant pediatric biologics use subcutaneous administration. The 11% share could rise as specialist recognition improves and long-term evidence accumulates for targeted treatment earlier in the disease course.

Adults: Adults dominate with an estimated 72% market share. This segment contains the broadest biologic eligibility, including therapies administered subcutaneously and through Intravenous Infusion. Adult patients can access multiple inflammatory mechanisms and dosing intervals ranging from approximately every 2 weeks to every 26 weeks. Long disease duration, repeated exacerbations and chronic corticosteroid exposure create strong clinical incentives for targeted therapy when severe eosinophilic inflammation is confirmed. Adults also account for the majority of specialist severe-asthma clinic populations and clinical-trial enrollment. The introduction of twice-yearly treatment is particularly relevant because reducing annual administration events from approximately 12 under monthly treatment to 2 can simplify long-term disease management. Adults are therefore expected to remain the largest application group through 2035.

Teenagers: Teenagers account for an estimated 17% share and represent an increasingly important transition population between pediatric and adult respiratory care. Several biologics are approved from 12 years of age, while others begin from 6 years, giving teenagers comparatively broad access to targeted treatment. A newly approved ultra-long-acting therapy covers patients aged 12 years and older and requires administration once every 6 months, potentially reducing treatment disruption for school-age patients. Adolescents can face adherence challenges with daily controller medicines, making less frequent biologic schedules potentially attractive when clinically appropriate. The estimated 17% share reflects a smaller population than Adults but a meaningful level of severe disease requiring specialist management.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America leads the Eosinophilic Asthma Treatment Market with an estimated 41% share. The United States drives regional adoption through established severe-asthma centers, broad availability of targeted biologics and extensive biomarker testing. Multiple biologic mechanisms are available, and age eligibility for selected severe eosinophilic asthma treatments extends to 6 years. This supports treatment across Children, Teenagers and Adults, although Adults remain dominant with approximately 72% of overall application demand. The region also hosts significant operations associated with AstraZeneca, Genentech (Roche Group) & Novartis, Regeneron Pharmaceuticals & Sanofi, and Teva Pharmaceuticals.

Innovation continues to reinforce North America's leadership. In December 2025, U.S. approval of an ultra-long-acting biologic for severe asthma with an eosinophilic phenotype introduced a 6-month administration interval for patients aged 12 years and older. The supporting program involved 762 patients treated across 331 sites in 23 countries, including approximately 25% of trial participants enrolled in the United States. This dosing model can reduce scheduled maintenance administrations to 2 annually, strengthening the region's movement toward more convenient precision therapy.

Europe

Europe represents an estimated 29% share, making it the second-largest regional market. Strong specialist respiratory networks in the U.K., Germany, France, Italy and other countries support biologic adoption. GSK and AstraZeneca maintain significant European roots within the supplied competitive landscape, while other multinational participants have broad regional operations. European severe-asthma management increasingly incorporates blood eosinophil testing and phenotype assessment before biologic selection. Treatment intervals ranging from 2 weeks to 6 months provide clinicians with multiple administration options.

Europe is also an important clinical-development region. Recent severe-asthma trials have enrolled patients across countries including France, Germany, Ireland, Poland, Spain, the Czech Republic and the U.K. The presence of multiple countries among a 23-nation development program illustrates the region's role in biologic research. With approximately 29% market share, Europe is expected to remain a major adoption center as extended-duration therapies and broader precision-medicine strategies become established through 2035.

Asia Pacific

Asia Pacific accounts for an estimated 22% share but is positioned as the fastest-growing regional market. Japan, China, South Korea and other markets are strengthening severe-asthma diagnostic capabilities and access to advanced biologic therapies. The region's large population means even modest increases in severe-asthma identification can translate into substantial numbers of treatment-eligible patients. Biomarker testing based on eosinophil counts such as 150 or 300 cells per microliter is becoming increasingly relevant for differentiating inflammatory phenotypes.

Clinical research is also becoming more geographically representative. China, Japan and Taiwan have participated in multinational development programs for advanced severe-asthma biologics, while overall programs have included more than 20 countries. Asia Pacific is estimated to expand at a rate exceeding 15% under the analytical framework, supported by rising specialist capacity and improving treatment availability. The region's approximately 22% current share therefore provides substantial headroom relative to North America's 41% position.

Latin America

Latin America represents approximately 5% of global treatment demand. Brazil, Mexico, Argentina and other larger healthcare markets provide the principal opportunities for biologic adoption. Access remains concentrated in specialist centers and larger urban healthcare systems, creating a substantial difference between potential need and treated patient numbers. Because biologics generally enter treatment at advanced management stages, expanding specialist referral is essential. Adults, representing approximately 72% of global application demand, are expected to account for most regional utilization.

The introduction of less frequently administered biologics could improve treatment logistics across geographically dispersed populations. Moving from 12 monthly treatment events to approximately 2 injections per year can substantially reduce travel requirements when clinically suitable. Latin America's estimated 5% share remains relatively small, but expansion of private healthcare, specialty respiratory services and biologic reimbursement creates gradual growth opportunities through 2035.

Middle East & Africa

Middle East & Africa accounts for approximately 3% of the market, reflecting uneven access to specialist severe-asthma treatment. Gulf countries possess advanced tertiary healthcare facilities and provide access to multiple biologics, while many lower-income markets continue to face limitations in diagnostic testing and specialist capacity. Severe eosinophilic asthma requires phenotype identification and long-term follow-up, creating infrastructure requirements beyond standard asthma management. Subcutaneous Injection, representing approximately 89% of global format demand, may provide advantages where infusion-center capacity is limited.

Longer administration intervals could become especially valuable in this region. A treatment schedule requiring only 2 maintenance injections annually offers substantial logistical advantages compared with approximately 13 visits for monthly administration. However, diagnostic availability, reimbursement and consistent treatment supply remain important constraints. The region's estimated 3% share is therefore expected to rise gradually rather than rapidly despite substantial unmet respiratory-care needs.

List of Top Eosinophilic Asthma Treatment Companies

• AstraZeneca
• GSK
• Genentech (Roche Group) & Novartis
• Regeneron Pharmaceuticals & Sanofi
• Teva Pharmaceuticals

Top 2 Companies Market Share

GSK: GSK is estimated to account for approximately 27% of the competitive position within the supplied company framework, supported by a long-established presence in IL-5-directed severe eosinophilic asthma treatment and the addition of an ultra-long-acting biologic platform. The company's latest extended-duration approach reduces maintenance administration to once every 6 months, equivalent to approximately 2 scheduled injections annually. This creates meaningful differentiation from treatments requiring every-4-week dosing. Its presence across established and next-generation biologic approaches strengthens its positioning among Adults and Teenagers while maintaining exposure to pediatric severe-asthma treatment through existing therapies.

AstraZeneca: AstraZeneca is estimated to represent approximately 24% of the supplied competitive framework, placing the combined analytical share of the 2 leading companies near 51%. Its severe eosinophilic asthma position is supported by IL-5 receptor-directed therapy with maintenance administration that can extend to every 8 weeks after initial dosing. Selected treatment is available for patients aged 6 years and older, expanding coverage across Children, Teenagers and Adults. AstraZeneca also participates in broader severe-asthma innovation through upstream inflammatory-pathway targeting, giving the company exposure to multiple biologic strategies as precision respiratory medicine evolves.

Investment Analysis

Investment in the Eosinophilic Asthma Treatment Market is increasingly focused on long-acting antibodies, biomarker-guided patient selection, self-administration systems and broader pediatric indications. The stated expansion from USD 36473.95 million in 2026 to USD 97532.91 million by 2035 at 38.8% CAGR creates a strong strategic incentive for continued clinical development. Administration convenience has become particularly important. Existing treatment intervals can range from every 2 weeks to every 8 weeks, while the newest ultra-long-acting approach extends dosing to approximately every 26 weeks. Reducing annual administration frequency from around 26 injections under a biweekly regimen to 2 under a twice-yearly regimen represents a potential reduction exceeding 90%, creating significant differentiation for next-generation products.

Investment is also moving toward identifying the most responsive patient populations. Blood eosinophil thresholds such as 150 cells per microliter and 300 cells per microliter are increasingly integrated with exacerbation history and other type 2 inflammatory markers. Clinical development programs now frequently operate across more than 20 countries, allowing companies to build broader datasets across diverse populations. Subcutaneous Injection attracts the majority of development interest because it represents approximately 89% of estimated format demand and can support home administration. Geographic investment is expected to increase in Asia Pacific, which currently represents approximately 22% of demand but offers significant long-term expansion potential.

New Product Development

New product development is centered on extending dosing duration without compromising exacerbation control. The most important recent advance is an ultra-long-acting subcutaneous antibody designed for administration once every 6 months. Its pivotal severe-asthma program studied 762 patients across 331 sites in 23 countries over approximately 52 weeks, demonstrating the scale required to establish efficacy and safety for extended-duration treatment. A 100 mg subcutaneous dose administered twice yearly significantly changes the treatment burden compared with monthly or biweekly regimens. Future development is likely to continue emphasizing antibody engineering that increases half-life, improves bioavailability and enables convenient injection devices.

Another development direction involves broader inflammatory targeting and improved phenotype matching. Severe asthma is increasingly treated according to measurable biological characteristics rather than symptoms alone. Multiple mechanisms now address IL-5, IL-5 receptor alpha, IL-4/IL-13 signaling and TSLP, giving clinicians at least 4 major inflammatory strategies relevant to advanced asthma care. Pediatric expansion is also important, with selected therapies now available from 6 years and newer extended-duration treatment from 12 years. Developers are therefore pursuing combinations of longer dosing, broader age eligibility and stronger biomarker-based differentiation to compete in an increasingly sophisticated market.

Five Recent Developments

• May 2026: AstraZeneca received an additional U.S. approval for its eosinophil-depleting biologic in another eosinophil-driven disorder after a Phase III study showed a 65% reduction in the risk of first disease flare, reinforcing the broader therapeutic potential of eosinophil targeting.
• December 2025: GSK secured U.S. approval for a new severe eosinophilic asthma biologic administered subcutaneously once every 6 months, establishing a twice-yearly maintenance schedule for eligible patients aged 12 years and older.
• November 2025: AstraZeneca reported positive Phase III results for eosinophil-directed treatment in hypereosinophilic disease, providing additional evidence for the therapeutic value of direct eosinophil depletion across inflammatory conditions.
• March 2025: GSK announced regulatory review progress for its ultra-long-acting biologic following positive late-stage asthma studies, with the development program designed around a 26-week dosing interval and reduced treatment burden.
• September 2024: AstraZeneca's severe eosinophilic asthma biologic continued its pediatric expansion following updated U.S. labeling supporting treatment from 6 years of age, broadening biologic eligibility across Children, Teenagers and Adults.

Report Coverage

The Eosinophilic Asthma Treatment Market analysis covers Intravenous Infusion and Subcutaneous Injection across Children, Adults and Teenagers. The supplied market trajectory moves from USD 26278.06 million in 2025 to USD 36473.95 million in 2026 and USD 97532.91 million by 2035 at the stated 38.8% CAGR. Product segmentation estimates Subcutaneous Injection at approximately 89% and Intravenous Infusion at approximately 11%. Application analysis estimates Adults at 72%, Teenagers at 17% and Children at 11%, totaling 100%. The analysis evaluates biologic administration frequency, eosinophil-based patient selection, pediatric eligibility, self-administration, specialist treatment pathways and long-acting antibody development across the 2026-2035 forecast period.

The competitive assessment covers AstraZeneca, GSK, Genentech (Roche Group) & Novartis, Regeneron Pharmaceuticals & Sanofi, and Teva Pharmaceuticals. Regional analysis estimates North America at 41%, Europe at 29%, Asia Pacific at 22%, Latin America at 5% and Middle East & Africa at 3%, representing 100% of the analytical geographic framework. Treatment-format analysis captures administration schedules ranging from approximately every 2 weeks to every 26 weeks, while age-based coverage reflects biologic eligibility extending as young as 6 years for selected treatments. The report also examines biomarker thresholds around 150 and 300 eosinophils per microliter, extended-duration treatment development, competitive differentiation, investment activity and evolving precision-medicine strategies shaping severe eosinophilic asthma care through 2035.